Optimizing Antifibrotic Therapy with Low-Dose Pirfenidone Plus Nintedanib versus High-Dose Pirfenidone or Nintedanib Monotherapy in Idiopathic Pulmonary Fibrosis (OPTIMA-IPF Study): A 36-Month Single-Centre Comparative Study
SHITAL VISHNU PATIL, GAJANAN GONDHALI et al. - Unknown